menu search

AIM / FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer

FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
The FDA has lifted the clinical hold on AIM ImmunoTech Inc's (NYSE: AIM) investigational new drug (IND) application for a Phase 2 study of Ampligen for locally advanced pancreatic cancer (AMP-270). The AMP-270 clinical trial's primary objective compares the efficacy of. Read More
Posted: Mar 16 2022, 11:59
Author Name: Benzinga
Views: 111574

AIM News  

AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

By GlobeNewsWire
September 22, 2023

AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAlee more_horizontal

AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference

By GlobeNewsWire
September 5, 2023

AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference

OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas more_horizontal

AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast

By GlobeNewsWire
August 9, 2023

AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast

OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that manageme more_horizontal

AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

By GlobeNewsWire
June 14, 2023

AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company fo more_horizontal

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

By GlobeNewsWire
March 27, 2023

AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company fo more_horizontal

AIM ImmunoTech broadens patent portfolio with new Netherlands utility patent

By Proactive Investors
January 9, 2023

AIM ImmunoTech broadens patent portfolio with new Netherlands utility patent

AIM ImmunoTech Inc (NYSE:AIM) has announced that the Netherlands Patent Office has granted the company a utility patent covering rugged dsRNA, a doubl more_horizontal

AIM ImmunoTech promotes Christopher McAleer to the role of scientific officer

By Proactive Investors
December 12, 2022

AIM ImmunoTech promotes Christopher McAleer to the role of scientific officer

AIM ImmunoTech Inc (NYSE:AIM) has announced the promotion of Christopher McAleer from the company's deputy scientific officer to the position of scien more_horizontal

AIM ImmunoTech reports positive safety, tolerability, and biological activity data from Phase 1 Ampligen study

By Proactive Investors
December 8, 2022

AIM ImmunoTech reports positive safety, tolerability, and biological activity data from Phase 1 Ampligen study

AIM ImmunoTech Inc (NYSE:AIM) has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal a more_horizontal


Search within

Pages Search Results: